Electronic nose technology was able to distinguish between multiple interstitial lung disease types with good accuracy.

That’s why the ATS [American Thoracic Society] recommended additional studies. There are some variations of pirfenidone being developed: an inhaled form as well as a modified form that might ...

I wasn’t involved in generating these guidelines, but the ATS [American Thoracic Society ... Whereas with pulmonary fibrosis–associated interstitial lung disease, it’s like 1 point in ...

Ongoing Phase 2 study enrolling 102 patients in the U.S. and South Korea, with more than 50% of participants identified as Asian ...

“The data presented at ATS 2023 underscore Veracyte’s commitment ... “Importantly, these findings suggest that our tests in interstitial lung disease and lung cancer are performing as ...

Maher, MD, of the University of Southern California in Los Angeles, at the American Thoracic Society (ATS) annual meeting in San Francisco ... While IPF is the most severe fibrotic ILD, other ILDs can ...

Joining the 2023 ACR/CHEST guideline for the treatment of ILD in people with SARDs is a 2024 guideline from the American Thoracic Society (ATS) focused on treatment of SSc-ILD. “You now have in ...

Two doses of 52-week nerandomilast, a phosphodiesterase 4B inhibitor, lowered FVC decline vs. placebo in patients with progressive pulmonary fibrosis, according to results published in The New England ...

ILD exacerbation frequency was also elevated with ... NO2 concentrations among individuals with respiratory disease," ATS 2023; Poster 925.

"We’re excited that our clinical users are sharing real-world experience with Fibresolve at the ATS Conference," said ... lung findings compatible with ILD. Bronchosolve is an investigational ...

and pulmonary hypertension associated with interstitial lung disease (PH-ILD) at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego ...